Company: RNGE
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023395
Chunk: 169

Company: RANGE IMPACT, INC.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part II, Item 8
Chunk 169
---
 for identical assets or similar assets or liabilities in inactive markets;

    ○
    Inputs
    other than quoted prices that are observable for the asset or liability;

    ○
    Inputs
    that are derived principally from or corroborated by observable market data by correlation or other means.

    ●
    Level
    3:
    Unobservable
    inputs that are not corroborated by market data

A
financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant
to the fair value measurement.

The
following is a description of the valuation methodologies used for instruments measured at fair value, including the general classification
of such instruments pursuant to the valuation hierarchy.

The
equipment held for sale is carried at the lower of carrying amount or fair value, and is considered level 2 as it is based on market
prices for similar assets.

    13

Segments

The
Company has two
operating business segments: (i) Range Land and (ii) Range Services. The Fola Mine, including the royalty and lease agreements
assigned in connection with the Fola Acquisition and the Winoc Acquisition, and the Hobet Mine are reported in the Range Land
operating business segment. Effective January 1, 2025, the business activities of the Range Reclaim, Range Security and Range Water
operating business segments, which had been previously-reported as separate operating business segments, are now captured as part of
the Range Services operating business segment. This change was implemented as each of these business segments now serve to support
the reclamation and improvement of the Company’s land holdings  and not as businesses serving other customers.
The change in the segment reporting is shown retrospectively in this filing. Graphium Biosciences was sold in September 2024 and
therefore the drug development business segment named Graphium Biosciences is no longer reported as an operating business segment of
the Company.

In
accordance with the “Segment Reporting” Topic of the ASC 280, the Company’s chief operating decision-maker has been
identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance
for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to
report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers,
and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation
under